Adicet Bio, Inc. ACET
We take great care to ensure that the data presented and summarized in this overview for Adicet Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACET
View all-
Orbimed Advisors LLC San Diego, CA11.4MShares$17.1 Million0.61% of portfolio
-
Tang Capital Management LLC San Diego, CA6.41MShares$9.55 Million1.83% of portfolio
-
Balyasny Asset Management LLC Chicago, IL6.18MShares$9.21 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY4.13MShares$6.16 Million0.16% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.11MShares$6.12 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.07MShares$6.06 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY4.01MShares$5.97 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.37MShares$5.03 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.13MShares$4.66 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC2.95MShares$4.39 Million0.51% of portfolio
Latest Institutional Activity in ACET
Top Purchases
Top Sells
About ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Insider Transactions at ACET
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 25
2024
|
Carl L Gordon |
BUY
Open market or private purchase
|
Indirect |
3,125,000
+28.21%
|
$6,250,000
$2.4 P/Share
|
|
Jan 25
2024
|
Orbimed Advisors LLC |
BUY
Open market or private purchase
|
Indirect |
3,125,000
+28.21%
|
$6,250,000
$2.4 P/Share
|
|
Jan 24
2024
|
Blake Aftab Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,700
+23.96%
|
-
|
|
Jan 24
2024
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,565
-7.69%
|
$7,130
$2.4 P/Share
|
|
Jan 24
2024
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,300
+20.53%
|
-
|
|
Jan 24
2024
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,957
-6.16%
|
$9,914
$2.4 P/Share
|
|
Jan 24
2024
|
Chen Schor President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
70,300
+25.19%
|
-
|
|
Jan 24
2024
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,290
-9.94%
|
$30,580
$2.4 P/Share
|
|
Jan 24
2024
|
Brian Nicholas Harvey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,300
+20.86%
|
-
|
|
Jan 24
2024
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,320
-5.55%
|
$8,640
$2.4 P/Share
|
|
Jan 24
2024
|
Don Healey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,700
+21.41%
|
-
|
|
Jan 24
2024
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,870
-8.47%
|
$9,740
$2.4 P/Share
|
|
Oct 12
2023
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,933
-14.61%
|
$7,933
$1.35 P/Share
|
|
Oct 02
2023
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,093
-9.14%
|
$8,093
$1.37 P/Share
|
|
Oct 02
2023
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,096
-8.36%
|
$7,096
$1.37 P/Share
|
|
Oct 02
2023
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,069
-13.62%
|
$9,069
$1.37 P/Share
|
|
Oct 02
2023
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,208
-13.11%
|
$23,208
$1.37 P/Share
|
|
Oct 02
2023
|
Chen Schor President & CEO |
BUY
Open market or private purchase
|
Indirect |
5,500
+11.23%
|
$5,500
$1.33 P/Share
|
|
Sep 29
2023
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Direct |
5,500
-3.01%
|
$5,500
$1.36 P/Share
|
|
Sep 28
2023
|
Chen Schor President & CEO |
BUY
Open market or private purchase
|
Direct |
5,500
+2.93%
|
$5,500
$1.42 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 204K shares |
|---|---|
| Open market or private purchase | 8.02M shares |
| Payment of exercise price or tax liability | 88.4K shares |
|---|---|
| Open market or private sale | 11K shares |